Prognostic Impact of Vitamin B6 Metabolism in Lung Cancer

SummaryPatients with non-small cell lung cancer (NSCLC) are routinely treated with cytotoxic agents such as cisplatin. Through a genome-wide siRNA-based screen, we identified vitamin B6 metabolism as a central regulator of cisplatin responses in vitro and in vivo. By aggravating a bioenergetic catastrophe that involves the depletion of intracellular glutathione, vitamin B6 exacerbates cisplatin-mediated DNA damage, thus sensitizing a large panel of cancer cell lines to apoptosis. Moreover, vitamin B6 sensitizes cancer cells to apoptosis induction by distinct types of physical and chemical stress, including multiple chemotherapeutics. This effect requires pyridoxal kinase (PDXK), the enzyme that generates the bioactive form of vitamin B6. In line with a general role of vitamin B6 in stress responses, low PDXK expression levels were found to be associated with poor disease outcome in two independent cohorts of patients with NSCLC. These results indicate that PDXK expression levels constitute a biomarker for risk stratification among patients with NSCLC.Graphical abstractGraphical AbstractHighlights► PDXK is required for optimal cisplatin responses in cancer cells ► PN, PDXK's substrate, aggravates CDDP cytotoxicity in vitro and in vivo ► Vitamin B6 metabolism affects cellular responses to multiple stress conditions ► PDXK expression levels influence disease progression in NSCLC patients